JACC: Cardiovascular Interventions
Volume 3, Issue 2 , Pages 203-212 , February 2010

Enoxaparin in Primary and Facilitated Percutaneous Coronary Intervention: A Formal Prospective Nonrandomized Substudy of the FINESSE Trial (Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events)

  • Gilles Montalescot, MD, PhD

      Affiliations

    • Pitiè-Salpêtrière University Hospital, Paris, France
    • Corresponding Author InformationReprint requests and correspondence: Dr. Gilles Montalescot, Institut de Cardiologie, INSERM U937, 47 Boulevard de l'Hôpital, 75013 Paris, France
    • ,
  • Stephen G. Ellis, MD

      Affiliations

    • Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Mark A. de Belder, MD

      Affiliations

    • The James Cook University Hospital, Middlesbrough, United Kingdom
    • ,
  • Luc Janssens, MD

      Affiliations

    • AZ Imelda Ziekenhuis, Bonheiden, Belgium
    • ,
  • Olivier Katz, MD

      Affiliations

    • Clinique Saint-Joseph, Colmar, France
    • ,
  • Wladyslaw Pluta, MD

      Affiliations

    • Wojewodzkie Centrum Medyczne, Opole, Poland
    • ,
  • Patrick Ecollan, MD

      Affiliations

    • Pitiè-Salpêtrière University Hospital, Paris, France
    • ,
  • Michal Tendera, MD

      Affiliations

    • Medical University of Silesia, Katowice, Poland
    • ,
  • Ad J. van Boven, MD

      Affiliations

    • Medisch Centrum Leeuwarden, Leeuwarden, the Netherlands
    • ,
  • Petr Widimsky, MD

      Affiliations

    • University Hospital FN Kralovske Vinohrady, Prague, Czech Republic
    • ,
  • Henning R. Andersen, MD

      Affiliations

    • Skejby University Hospital, Aarhus, Denmark
    • ,
  • Amadeo Betriu, MD

      Affiliations

    • Hospital Clinic I Provincial, Barcelona, Spain
    • ,
  • Paul Armstrong, MD

      Affiliations

    • University of Alberta Hospital, Edmonton, Alberta, Canada
    • ,
  • Bruce R. Brodie, MD

      Affiliations

    • LeBauer Cardiovascular Research, Greensboro, North Carolina
    • ,
  • Howard C. Herrmann, MD

      Affiliations

    • University of Pennsylvania Medical Center, Philadelphia, Pennsylvania
    • ,
  • Franz-Josef Neumann, MD

      Affiliations

    • Herz-Zentrum Bad Krozingen, Bad Krozingen, Germany
    • ,
  • Mark B. Effron, MD

      Affiliations

    • Eli Lilly and Company, Indianapolis, Indiana
    • ,
  • Jiandong Lu, PhD

      Affiliations

    • Centocor Research and Development, Inc., Malvern, Pennsylvania
    • ,
  • Elliot S. Barnathan, MD

      Affiliations

    • Centocor Research and Development, Inc., Malvern, Pennsylvania
    • ,
  • Eric J. Topol, MD

      Affiliations

    • The Scripps Research Institute and Scripps Clinic, La Jolla, California
    • ,
  • FINESSE Investigators

Received 13 July 2009 ,Revised 19 October 2009 ,Accepted 13 November 2009.

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.

 This work was supported by Centocor, Inc., Malvern, Pennsylvania, and Eli Lilly, Indianapolis, Indiana. Dr. Montalescot reports receiving consulting fees, speaking fees, and research grant support from Eli Lilly and Sanofi-Aventis. Dr. Ellis reports being employed and Dr. Topol reports having been employed by the Cleveland Clinic, which received research funds from Eli Lilly and Centocor to assist in the coordination of this study. Dr. de Belder reports receiving advisory board fees from Eli Lilly, fees provided for the United Kingdom coordination of the FINESSE trial, and lecture fees from Eli Lilly. Dr. Armstrong reports receiving research grants from Schering-Plough, Boehringer Ingelheim, and Hoffmann-La Roche. Dr. Effron reports being employed by Eli Lilly. Dr. Widimsky reports receiving consulting fees and speaking fees from Eli Lilly. Dr. Andersen reports receiving speaking fees and research grants from Eli Lilly. Dr. Herrmann reports receiving speaking fees from Schering-Plough and research grants from the Medicines Company, Conor Medsystems, and Schering-Plough. Drs. Barnathan and Lu report being employed by Centocor.

PII: S1936-8798(09)00832-2

doi: 10.1016/j.jcin.2009.11.012

JACC: Cardiovascular Interventions
Volume 3, Issue 2 , Pages 203-212 , February 2010

Article Tools

* Image Usage & Resolution